{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=94",
    "query": {
      "condition": "Gastrointestinal Carcinoma",
      "page": 94
    },
    "page_size": 10
  },
  "pagination": {
    "page": 94,
    "page_size": 10,
    "total_count": 2738,
    "total_pages": 274,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=95&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=93&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-06T08:50:48.266Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03439891",
      "title": "Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage IIIA Hepatocellular Carcinoma AJCC v8",
        "Stage IIIB Hepatocellular Carcinoma AJCC v7",
        "Stage IIIC Hepatocellular Carcinoma AJCC v7",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IVA Hepatocellular Carcinoma AJCC v8",
        "Stage IVB Hepatocellular Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Robin Kate Kelley",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2018-04-16",
      "completion_date": "2023-11-30",
      "has_results": true,
      "last_update_posted_date": "2025-02-11",
      "last_synced_at": "2026-11-06T08:50:48.266Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • San Francisco, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03439891"
    },
    {
      "nct_id": "NCT04407247",
      "title": "Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colitis",
        "Lung Non-Small Cell Carcinoma",
        "Malignant Genitourinary System Neoplasm",
        "Malignant Solid Neoplasm",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Infliximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vedolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2020-07-09",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-11-06T08:50:48.266Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04407247"
    },
    {
      "nct_id": "NCT01195415",
      "title": "Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Pancreatic Carcinoma",
        "Stage IV Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Vismodegib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2010-06",
      "completion_date": "2014-10-10",
      "has_results": true,
      "last_update_posted_date": "2017-08-07",
      "last_synced_at": "2026-11-06T08:50:48.266Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01195415"
    },
    {
      "nct_id": "NCT03785210",
      "title": "Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Hepatocellular Cancer",
        "Metastatic Pancreatic Cancer",
        "Metastatic Colorectal Cancer",
        "Liver Metastasis"
      ],
      "interventions": [
        {
          "name": "nivolumab",
          "type": "DRUG"
        },
        {
          "name": "tadalafil",
          "type": "DRUG"
        },
        {
          "name": "oral vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2019-06-05",
      "completion_date": "2022-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-11-06T08:50:48.266Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03785210"
    },
    {
      "nct_id": "NCT06285097",
      "title": "A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Non-small-cell Lung Cancer",
        "Melanoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Renal Cell Carcinoma",
        "Urothelial Carcinoma",
        "Colorectal Carcinoma",
        "Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "PF-07820435",
          "type": "DRUG"
        },
        {
          "name": "Sasanlimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2024-02-08",
      "completion_date": "2025-02-13",
      "has_results": false,
      "last_update_posted_date": "2025-09-17",
      "last_synced_at": "2026-11-06T08:50:48.266Z",
      "location_count": 6,
      "location_summary": "Sarasota, Florida • Grand Rapids, Michigan • Nashville, Tennessee",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06285097"
    },
    {
      "nct_id": "NCT07903415",
      "title": "A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma",
        "Esophageal Cancer",
        "Carcinoma, Non-Small-Cell Lung (NSCLC)",
        "Gastric Carcinoma",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "PF-08098488",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2026-10-29",
      "completion_date": "2032-01-26",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-06T08:50:48.266Z",
      "location_count": 4,
      "location_summary": "Grand Rapids, Michigan • Nashville, Tennessee • San Antonio, Texas",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07903415"
    },
    {
      "nct_id": "NCT04752384",
      "title": "Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Buprenorphine",
          "type": "DRUG"
        },
        {
          "name": "Tramadol",
          "type": "DRUG"
        },
        {
          "name": "Oral Mucositis (OM) Pain App",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2021-07-08",
      "completion_date": "2024-04-04",
      "has_results": true,
      "last_update_posted_date": "2025-04-20",
      "last_synced_at": "2026-11-06T08:50:48.266Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04752384"
    },
    {
      "nct_id": "NCT01383343",
      "title": "Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Colon Carcinoma",
        "Recurrent Rectal Carcinoma",
        "Stage IVA Colon Cancer",
        "Stage IVA Rectal Cancer",
        "Stage IVB Colon Cancer",
        "Stage IVB Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2011-08",
      "completion_date": "2017-02",
      "has_results": false,
      "last_update_posted_date": "2017-04-19",
      "last_synced_at": "2026-11-06T08:50:48.266Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01383343"
    },
    {
      "nct_id": "NCT01005875",
      "title": "Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Body Radiotherapy (SBRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2009-11",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2017-05-10",
      "last_synced_at": "2026-11-06T08:50:48.266Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01005875"
    },
    {
      "nct_id": "NCT05433142",
      "title": "Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "XmAb819",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 307,
      "start_date": "2022-06-13",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-11-06T08:50:48.266Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Duarte, California • Sacramento, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05433142"
    }
  ]
}